Goldman Sachs Stock (GS) Rises on Dec. 18, 2025: Latest News, Analyst Price Targets, and the 2026 Outlook

Goldman Sachs Stock (GS) Rises on Dec. 18, 2025: Latest News, Analyst Price Targets, and the 2026 Outlook

December 18, 2025 — Goldman Sachs Group, Inc. (NYSE: GS) is ending 2025 in the middle of a powerful Wall Street narrative: easing inflation pressures, a late-year equities rally, and a dealmaking cycle that is flirting with record territory. Those themes intersect today in a way that matters for Goldman Sachs stock, because GS is not just another bank—it is a capital-markets machine whose earnings power tends to expand when underwriting, M&A, and trading activity improve.

By early afternoon, GS shares were trading around the high-$870s, up modestly on the day. [1]

Goldman Sachs stock today: what moved GS on December 18, 2025?

Two market forces dominated the tape on Dec. 18, 2025:

1) Softer inflation data, louder rate-cut chatter
A Reuters market report says U.S. consumer inflation (CPI) rose 2.7% year-over-year in November, below the 3.1% consensus forecast, while core CPI (ex-food and energy) was 2.6%. The data was complicated by a government shutdown that disrupted monthly comparisons, but markets still treated the release as supportive for risk assets. [2]

From the perspective of Goldman Sachs stock, this macro backdrop can be a double-edged sword:

  • Easing inflation and lower yields can boost overall risk appetite and capital markets activity.
  • But falling yields can pressure interest-sensitive parts of the financial sector, especially if rate cuts accelerate.

Notably, Goldman Sachs Asset Management’s Kay Haigh cautioned (via Reuters) that the inflation reading may be “noisy,” and suggested the Fed may focus more heavily on December CPI, due mid-January—right before the next policy meeting. [3]

2) A Dow-driven move amplified GS’s visibility
MarketWatch noted that early Thursday, gains in Goldman Sachs and Home Depot were major contributors to a roughly 218-point advance in the Dow Jones Industrial Average, with GS up about $14.99 (1.7%) in that window. [4]

In other words: even a “normal” up day in GS can look bigger when it’s moving the Dow.

The Goldman Sachs headlines investors are reading right now

While the broader market set the tone, several Goldman-specific news items are shaping the near-term narrative around GS stock.

Goldman adds a high-profile tech banker as it pushes deeper into software dealmaking

Reuters reported Goldman hired Brian Cayne, a Qatalyst Partners co-founder, to become global co-head of its software investment banking practice starting in January 2026. The report said Cayne will be based in San Francisco and co-lead alongside existing regional co-heads, reporting into Goldman’s TMT leadership. [5]

Why this matters for GS stock:
Goldman is effectively doubling down on one of Wall Street’s most lucrative fee pools—software and tech M&A—at the exact moment the industry is re-accelerating.

Reuters also highlighted Goldman’s positioning in the space: No. 1 in global technology M&A by deal value in 2025, advising on $337.8 billion of transactions for a 42.5% market share, per LSEG data cited by Reuters. [6]

Goldman’s TMT reorg underscores the “digital infrastructure + AI” thesis

Earlier this week, Reuters reported Goldman restructured parts of its influential technology, media, and telecom (TMT) investment banking group to focus more on digital infrastructure and AI-driven deals, forming new sector groupings and leadership roles. [7]

Why this matters:
This is the kind of internal plumbing change investors often ignore—until it shows up in league tables, mandates, and fee revenue.

Carlyle taps Goldman on a complex, geopolitically sensitive deal

Reuters also reported Carlyle hired Goldman Sachs to advise on a bid for Lukoil’s overseas assets, valued at about $22 billion, a process complicated by sanctions and U.S. Treasury clearance requirements (with Reuters noting a January 17 deadline to conclude talks). [8]

Why this matters for GS stock:
Whether or not the deal closes, it highlights Goldman’s “complexity advantage” in transactions where regulatory, geopolitical, and cross-border factors raise the bar.

Goldman Sachs Alternatives leads a $100M AI funding round

A Business Wire release said Neural Concept raised a $100 million Series C round led by Growth Equity at Goldman Sachs Alternatives, with proceeds aimed at scaling its AI-native engineering platform. [9]

For investors, this is a reminder that Goldman is not only advising on AI-era deal flow—it’s also deploying capital through its alternatives platform. The same release describes Goldman Sachs Alternatives as having over $500 billion in alternatives assets and notes Goldman Sachs has approximately $3.5 trillion in assets under supervision (as of Sept. 30, 2025). [10]

The bigger catalyst: M&A is booming again—and 2025 is near record-breaking

For many investors, the most important GS stock driver into 2026 is simple: the deal machine appears to be back.

A Reuters deep dive on global M&A says:

  • Global M&A value has surpassed $4.8 trillion (second-highest year on record), with deals up 41% versus 2024 (as of Dec. 16, per Dealogic data cited by Reuters). [11]
  • There have been a record 70 deals above $10 billion, with 22 of those in Q4 alone. [12]
  • Bankers expect momentum to carry into 2026, helped by favorable market conditions and a more permissive U.S. regulatory environment (as described by Reuters). [13]

Reuters also cited Citi’s Drago Rajkovic saying there are $50–$70 billion deals “in the system” for 2026—and that a $100 billion tech deal isn’t out of the question. [14]

Why this matters for Goldman Sachs stock:
Goldman’s earnings tend to benefit when (1) advisory pipelines are strong, (2) underwriting reopens, and (3) market volatility and liquidity drive client activity. A sustained “M&A run” can support both revenue growth and investor confidence in the durability of returns.

Goldman’s own market view: 2026 may reward stock pickers

A MarketWatch report attributed to Goldman Sachs said the firm expects 2026 to be a strong year for stock picking, citing an outlook for low correlation among S&P 500 constituents (more dispersion). It also pointed to typical seasonal strength into year-end and noted the S&P 500 was still close to its highs. [15]

For GS stock, this theme matters because dispersion and active positioning can support:

  • Institutional trading volumes,
  • Hedging activity,
  • Prime brokerage and financing demand,
  • And advisory opportunities in sectors where winners and losers diverge.

Analyst forecasts for Goldman Sachs stock: price targets, ratings, and what’s changed in December

Wall Street’s published targets paint a clear picture: GS has had a big run, and forecasts are now split between “still like it” and “wait for a better entry.”

MarketBeat: “Hold” consensus, targets below the current price

MarketBeat’s compilation (as of Dec. 18) shows:

  • Consensus rating: Hold, based on 22 analysts (1 sell, 17 hold, 4 buy). [16]
  • Average 12-month price target: $792.67, with a high of $971 and a low of $600—implying a forecasted downside of about -9.6% from the quoted level on the page. [17]
  • A notable recent change: Keefe, Bruyette & Woods raised its target from $870 to $971 (dated 12/17/2025 in MarketBeat’s table). [18]

TipRanks: “Moderate Buy,” with targets in the low-$800s

TipRanks’ snapshot shows:

  • Moderate Buy (14 analysts in the last 3 months), with an average target around $832.58 and a $750–$900 range. [19]

BofA: bullish on momentum and a “super cycle” in M&A

An Investing.com report said BofA Securities raised its price target to $900 from $850 (published Dec. 8, 2025) and kept a Buy rating, citing “significant momentum” in revenue growth and highlighting M&A, wealth management, and private credit, plus productivity improvements (including AI initiatives). [20]

How to interpret the spread
When one consensus says “Hold” with targets below the current price while others still show “Moderate Buy,” it usually means:

  • The fundamental story is intact, but
  • The valuation and expectations are less forgiving after a strong rally.

Earnings watch: what investors should monitor next

The next major scheduled catalyst for Goldman Sachs stock is the next earnings report.

TipRanks lists Goldman’s upcoming earnings date as Jan. 15, 2026 (before market open) and shows a consensus EPS estimate of $11.54 for the upcoming quarter (with last year’s comparable quarter at $11.95). [21]

For context on the most recent results, MarketBeat’s earnings summary reports that Goldman’s last quarterly release (dated Oct. 14, 2025) delivered:

  • EPS of $12.25 vs. $10.27 expected, and
  • Revenue of $15.18B vs. $13.68B expected. [22]

Bull case vs. bear case for GS stock into 2026

The bull case for Goldman Sachs stock

Dealmaking momentum stays hot. If M&A remains near record pace—as Reuters suggests—Goldman’s advisory franchise could benefit from high-fee mega-deals and improved financing windows. [23]

Tech and AI are becoming a bigger “fee pool.” Goldman’s TMT restructuring and its high-profile hire in software banking signal the firm is positioning to capture AI-era infrastructure and platform consolidation. [24]

Alternatives and private markets keep scaling. The Neural Concept deal is small in the context of Goldman, but it reinforces a broader push in alternatives and growth equity—areas many investors view as strategically important for long-term earnings mix. [25]

The bear case for Goldman Sachs stock

Expectations are high. Multiple analyst compendiums show price targets clustering below (or not far above) where the stock trades, which can limit upside unless earnings surprise or guidance improves. [26]

Macro cross-currents. Today’s CPI surprise helped risk sentiment, but even Reuters notes data quality issues tied to the shutdown—and Goldman’s own GSAM commentary warns the Fed may need cleaner data before acting. That uncertainty can swing rates, volatility, and deal confidence. [27]

Regulatory/geopolitical complexity can cut both ways. High-complexity mandates (like sanctions-tangled asset sales) can be lucrative, but they also carry higher execution and headline risk. [28]

Bottom line on Goldman Sachs stock on Dec. 18, 2025

As of December 18, 2025, Goldman Sachs stock (GS) sits at the intersection of three bullish forces—cooling inflation, improving risk appetite, and an M&A cycle that Reuters says is approaching record levels—plus one clear restraint: valuation and expectations after a strong run.

For investors and readers tracking GS stock news, the near-term checklist is straightforward:

  • Watch whether the year-end rally continues and whether capital markets activity stays strong.
  • Track the pace of mega-deal announcements into early 2026.
  • Monitor expectations for the next earnings report (mid-January), which could reset sentiment quickly. [29]
Goldman Sachs’ Shocking Stock Market Warning!

References

1. www.marketbeat.com, 2. www.reuters.com, 3. www.reuters.com, 4. www.marketwatch.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.businesswire.com, 10. www.businesswire.com, 11. www.reuters.com, 12. www.reuters.com, 13. www.reuters.com, 14. www.reuters.com, 15. www.marketwatch.com, 16. www.marketbeat.com, 17. www.marketbeat.com, 18. www.marketbeat.com, 19. www.tipranks.com, 20. www.investing.com, 21. www.tipranks.com, 22. www.marketbeat.com, 23. www.reuters.com, 24. www.reuters.com, 25. www.businesswire.com, 26. www.marketbeat.com, 27. www.reuters.com, 28. www.reuters.com, 29. www.tipranks.com

Stock Market Today

  • AB Science Initiates Coverage by Maxim Group with €4 Target Price
    December 18, 2025, 2:35 PM EST. AB Science announces that Maxim Group has initiated coverage of its stock with a Buy rating and a €4.00 target price. The US-based investment bank published a study titled Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS, dated December 18, 2025, highlighting masitinib's potential across neurodegenerative diseases and a favorable risk-benefit profile. Maxim notes data supporting neuroprotection in progressive MS and mild AD, while stating the models for AD or MS are upside. The initiation adds to other analysts covering AB Science, including Chardan, In Extenso Finance, and DNA Finance. AB Science, focused on PKIs for high-need diseases, is listed on Euronext Paris (ticker: AB).
Applied Materials (AMAT) Stock News Today: Analyst Price Targets Shift Higher as AI Chip Equipment Forecasts Strengthen (Dec. 18, 2025)
Previous Story

Applied Materials (AMAT) Stock News Today: Analyst Price Targets Shift Higher as AI Chip Equipment Forecasts Strengthen (Dec. 18, 2025)

Ondas Holdings (ONDS) Stock Today (Dec. 18, 2025): Shares Rally on Demining Pilot Results, New COO, and Fresh Analyst Targets
Next Story

Ondas Holdings (ONDS) Stock Today (Dec. 18, 2025): Shares Rally on Demining Pilot Results, New COO, and Fresh Analyst Targets

Go toTop